BioPharma Resources

Drug Trial Radar · NCT07491497

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Mar 11, 2026

Primary completion

May 31, 2029

Study completion Jan 30, 2034

Sponsor

Lead sponsor
TRIANA Biomedicines, Inc.Industry
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: * Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing * Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter * Keep a diary of each time they take the study medication

Conditions

  • ALK-positive NSCLC
  • ALK-Positive Lung Cancer
  • ALK-positive Non-small Cell Lung Cancer

Interventions

  • TRI-611Drug

    oral ALK molecular glue degrader

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Treatment emergent adverse eventsTime frame: Within 28 days of the first TRI-611 dose
  2. Part 2: Objective response rate (ORR)Time frame: Approximately 16 weeks after the last participant dosed in Part 2
  3. Part 2: Depth of response (DofR)Time frame: Approximately 16 weeks after the last participant dosed in Part 2

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • UCSF

    San Francisco, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Center

    Boston, Massachusetts · Recruiting

  • Washington University Medical Center

    St Louis, Missouri · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Oncology Consultants Research (P1 Trials)

    Houston, Texas · Recruiting

  • START-Mountain Region

    West Valley City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Royal North Shore Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Gustave Roussy Institute

    Villejuif, France · Recruiting

  • The Royal Marsden NHS Foundation

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.